
Terry Katz, CEO and co-founder of ForgeStop Technology Corporation, explains how its connected technology can enhance anticounterfeiting and how data are handled within the product.
In Part I of this two-part series, the authors discuss the need to follow GMPs for lipid-vesicle fabrication that result in size uniformity, delivery of sufficient drug concentration, and stability.
over 24 years ago
The Usefulness of 0.45 µm–Rated Filter Membranesover 24 years ago
Outsourcing Outlookover 24 years ago
Monitoring Blend Uniformity with Effusivityover 24 years ago
Bush Budget Combats Bioterrorism, Promotes Drug Safety





